Ibudilast slows grey matter and whole brain atrophy but has no impact on brain lesion counts in primary or secondary progressive MS, new results from the anti-inflammatory agent show. A secondary analysis of the 2018 SPRINT-MS study, which compared ibudilast with placebo over 96 weeks, found a 35% treatment effect on grey matter atrophy with ...
Novel agent slows grey matter atrophy in MS but neuroprotection is not black and white
By Mardi Chapman
11 Feb 2021